Table 2.
Study outcomes.
| Outcomes | Intervention (45 FN Episodes), No. (%) |
Control (45 FN Episodes), No. (%) |
p Value |
|---|---|---|---|
| Overall appropriateness | 40 (88.9) | 23 (51.1) | <0.001 |
| Step 1 Empirical therapy | 44 (97.8) | 35 (77.8) | 0.007 |
| Appropriate Indication | 45 (100) | 45 (100) | - |
| Appropriate coverage | 45 (100) | 41 (91.1) | 0.041 |
| Appropriate dosage regimen | 44 (97.8) | 39 (88.7) | 0.049 |
| Step 2 Documentation therapy | 40 (88.9) b | 29 (64.4) | 0.004 |
| Appropriate indication | 43 (95.6) | 41 (91.1) | 0.361 |
| Appropriate dosage regimen | 44 (97.8) | 43 (93.3) | 0.242 |
| Appropriate duration | 41 (91.1) | 34 (75.6) | 0.039 |
| Length of stay, median days (IQR) | 28 (19–42) | 23 (16–35) | 0.689 |
| 30-day infectious diseases related mortality | 6 (13.6) | 5 (11.1) | 1.000 |
| Total antibiotic duration, median days (IQR) | 14 (10–23) | 15 (10–21) | 0.948 |
| antibiotic duration in de-escalation | 21 (14–28) | 17.5 (15.5–29.5) | 0.666 |
| antibiotic duration in escalation | 19 (13–34.5) | 15 (11–25.5) | 0.309 |
FN, febrile neutropenia; IQR, interquartile range. b Total 44 FN episodes since one death occurred before culture was reported.